References
1. Panaitescu, Syngelaki, Prodan, Akolekar, Nicolaides. Chronic hypertension and adverse pregnancy outcome: a cohort study.Ultrasound Obstet Gynecol . 2017;50(2):228-35.
2. Fox, McHugh, Browne, Kenny, Fitzgerald, Khashan,et al. Estimating the Cost of Preeclampsia in the Healthcare System: Cross-Sectional Study Using Data From SCOPE Study (Screening for Pregnancy End Points).Hypertension . 2017;70(6):1243-9.
3. Wright, Rolnik, Syngelaki, de Paco Matallana, Machuca, de Alvarado,et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. Am J Obstet Gynecol . 2018;218(6):612.e1-.e6.
4. Rolnik, Wright, Poon, O’Gorman, Syngelaki, de Paco Matallana,et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med . 2017;377(7):613-22.
5. NICE. Hypertension in pregnancy: diagnosis and management. 2019.
6. Tan, Wright, Syngelaki, Akolekar, Cicero, Janga,et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol . 2018;51(6):743-50.
7. Askie, Duley, Henderson-Smart, Stewart. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.Lancet . 2007;369(9575):1791-8.
8. O’Gorman, Wright, Poon, Rolnik, Syngelaki, Wright,et al. Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet Gynecol . 2017;49(6):751-5.
9. Guy, Leslie, Diaz Gomez, Forenc, Buck, Khalil,et al. Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study. Bjog . 2021;128(2):149-56.
10. Guy, Leslie, Diaz Gomez, Forenc, Buck, Bhide,et al. Effect of routine first-trimester combined screening for pre-eclampsia on small-for-gestational-age birth: secondary interrupted time series analysis. Ultrasound Obstet Gynecol . 2022;59(1):55-60.
11. Lourenço, Gomes, Ribeiro, Caeiro, Rocha, Francisco. Screening for Preeclampsia in the First Trimester and Aspirin Prophylaxis: Our First Year. Rev Bras Ginecol Obstet . 2020;42(7):390-6.
12. NICE. Antenatal care. 2021.
13. Tranquilli, Dekker, Magee, Roberts, Sibai, Steyn,et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens . 2014;4(2):97-104.
14. Marsál, Persson, Larsen, Lilja, Selbing, Sultan. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr . 1996;85(7):843-8.
15. Shanmugalingam, Wang, Motum, Fulcher, Lee, Kumar,et al. Clinical Influence of Nonadherence With Prophylactic Aspirin in Preventing Preeclampsia in High-Risk Pregnancies: A Multicenter, Prospective, Observational Cohort Study. Hypertension . 2020;75(4):1125-32.
16. Wright, Poon, Rolnik, Syngelaki, Delgado, Vojtassakova,et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol . 2017;217(6):685.e1-.e5.
17. Dubon Garcia, Devlieger, Redekop, Vandeweyer, Verlohren, Poon. Cost-utility of a first-trimester screening strategy versus the standard of care for nulliparous women to prevent pre-term pre-eclampsia in Belgium. Pregnancy Hypertens . 2021;25:219-24.
18. Mewes, Lindenberg, Vrijhoef. Cost-effectiveness analysis of implementing screening on preterm pre-eclampsia at first trimester of pregnancy in Germany and Switzerland. PLoS One . 2022;17(6):e0270490.
19. Zakiyah, Tuytten, Baker, Kenny, Postma, van Asselt. Early cost-effectiveness analysis of screening for preeclampsia in nulliparous women: A modelling approach in European high-income settings. PLoS One . 2022;17(4):e0267313.
20. Park, Deeming, Bennett, Hyett. Cost-effectiveness analysis of a model of first-trimester prediction and prevention of preterm pre-eclampsia compared with usual care. Ultrasound Obstet Gynecol . 2021;58(5):688-97.
21. Ortved, Hawkins, Johnson, Hyett, Metcalfe. Cost-effectiveness of first-trimester screening with early preventative use of aspirin in women at high risk of early-onset pre-eclampsia. Ultrasound Obstet Gynecol . 2019;53(2):239-44.
22. Rolnik, Selvaratnam, Wertaschnigg, Meagher, Wallace, Hyett,et al. Routine first trimester combined screening for preterm preeclampsia in Australia: A multicenter clinical implementation cohort study. Int J Gynaecol Obstet . 2022;158(3):634-42.
23. Wright, Tan, O’Gorman, Syngelaki, Nicolaides. Serum PlGF compared with PAPP-A in first trimester screening for preterm pre-eclampsia: Adjusting for the effect of aspirin treatment. Bjog . 2022;129(8):1308-17.
24. Harmon, Huang, Umbach, Klungsøyr, Engel, Magnus,et al. Risk of fetal death with preeclampsia. Obstet Gynecol . 2015;125(3):628-35.
25. Hastie, Tong, Wikström, Sandström, Hesselman, Bergman. Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. Am J Obstet Gynecol . 2021;224(1):95.e1-.e12.
26. Szende, Janssen, Cabases. Self-Reported Population Health: An International Perspective based on EQ-5D. Dordrecht (NL): Springer
Copyright 2014, The Editor(s) (if applicable) and the Author(s). 2014.
27. van der Nelson, Draycott, Siassakos, Yau, Hatswell. Carbetocin versus oxytocin for prevention of post-partum haemorrhage at caesarean section in the United Kingdom: An economic impact analysis. Eur J Obstet Gynecol Reprod Biol . 2017;210:286-91.
28. NICE. Economic analysis of smoking cessation in secondary care: NICE public health guidance. 2013.
29. Kuppermann, Nease, Learman, Gates, Blumberg, Washington. Procedure-related miscarriages and Down syndrome-affected births: implications for prenatal testing based on women’s preferences.Obstet Gynecol . 2000;96(4):511-6.
30. Hunter, Beardmore-Gray, Greenland, Linsell, Juszczak, Hardy,et al. Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX). PharmacoEconomics - Open . 2022.